Evolving directions in obesity management

J Fam Pract. 2014 Jul;63(7 Suppl):S27-33.

Abstract

Over the past decade, treatment for obesity has been limited because of an incomplete understanding of the pathophysiology of obesity, lack of recognition of it as a disease, and limited efficacy of treatment options. Safety concerns related to medical and surgical approaches for obesity have also been a major barrier. The challenging nature of obesity management is reflected in a survey of primary care physicians which indicated that treating patients with obesity can be as difficult as treating patients with nicotine or alcohol dependence.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents / therapeutic use*
  • Bupropion / therapeutic use
  • Dopamine Uptake Inhibitors / therapeutic use
  • Forecasting
  • Glucagon-Like Peptide 1 / analogs & derivatives
  • Glucagon-Like Peptide 1 / therapeutic use
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Incretins / therapeutic use
  • Liraglutide
  • Naltrexone / therapeutic use
  • Narcotic Antagonists / therapeutic use
  • Obesity / prevention & control*
  • Receptors, Glucagon / agonists

Substances

  • Anti-Obesity Agents
  • Dopamine Uptake Inhibitors
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Incretins
  • Narcotic Antagonists
  • Receptors, Glucagon
  • Bupropion
  • Naltrexone
  • Liraglutide
  • Glucagon-Like Peptide 1